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programmes, epidemiological data on the incidence and prevalence of TB, and mortality rates. Only limited details were provided in the paper. However, the reader is referred to a downloadable appendix for full details of all parameters.
Modelling
Initially, a published epidemiological model was calibrated with corresponding regional data from 1950 to 2000 to provide the incidence of TB, prevalence and mortality for the relevant region. This model was then used to project the incidence of TB, prevalence and mortality for the period 2000 to 2100 for a base-case of no intervention, then subsequently for the other scenarios. These projected data were then combined with health state valuations using a published population model (PopMod; Lauer et al. 2003 , see 'Other Publications of Related Interest' below for bibliographic details) to allow the population impact of the various intervention strategies to be captured. The final population model had a lifetime horizon. Full details on all aspects of the modelling were provided in an appendix to the paper.
Sources searched to identify primary studies
The clinical data were based on published sources, although details of the study designs were not provided. Much of the epidemiological data were obtained from UNAIDS databases. The mortality data were based on WHO estimates.
Methods used to judge relevance and validity, and for extracting data
The process used to identify the data was not reported; only data relevant to the two regions appears to have been used. No inclusion criteria were specified for any parameters. Although published models were used, it is unclear whether the methodology was reported in these papers.
Measure of benefits used in the economic analysis
The summary measure of benefit used was the disability-adjusted life-years (DALYs) averted. Health state valuations were taken from the literature. Details of the methods used to value the health states were not provided.
Direct costs
The direct costs included were those of the service provider (WHO). These covered diagnostic tests, drug use, health centre visits for supervision and monitoring, and hospitalisation. Resource use was based on WHO treatment protocols and expert opinion. The unit costs of health centre visits and hospital inpatient days were derived from a published study. The drug costs were estimated using WHO negotiated prices, with a mark-up for international and local transportation costs. The costs of diagnostic testing were based on the best available international costing data from the WHO cost database. Limited cost data were provided in the paper. However, full details, including separated resource use and unit costs, were provided in the appendix. It was unclear if discounting was conducted. The price year was 2000.
Statistical analysis of costs
The resource use and cost data were treated deterministically.
Indirect Costs
The productivity costs do not appear to have been included, although they would have been relevant from a societal perspective.
